Can two drugs together tackle tough lung cancer?
NCT ID NCT04797702
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial is testing whether combining two drugs—glumetinib and toripalimab—can help people with advanced non-small cell lung cancer that has not responded to or is no longer controlled by standard treatments. The study is enrolling adults whose cancer has a specific marker (PD-L1 expression of 1% or higher) and who do not have certain genetic mutations. The goal is to see if the combination is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of two drugs: glumetinib (a MET inhibitor) and toripalimab (an immunotherapy)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced non-small cell lung cancer who have run out of standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits and risks are not yet clear. The combination may cause significant side effects, and it is unknown if it will work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510180, China